Market Access/ News/ News Bayer’s Aliqopa gets speedy review for marginal zone lymphoma George Underwood Aliqopa, Bayer, copanlisib, lymphoma, PI3K 0 Comment The FDA has granted Breakthrough Therapy Designation to Bayer’s PI3K inhibitor Aliqopa (copanlisib) for marginal zone lymphoma (MZL) Share X Bayer’s Aliqopa gets speedy review for marginal zone lymphoma https://pharmaphorum.com/news/bayers-aliqopa-gets-speedy-review-for-marginal-zone-lymphoma/
